BiondVax Pharmaceuticals (NASDAQ: BVXV), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax’s Universal Flu Vaccine is based on research carried out over two decades by Weizmann Institute of Science Professor Ruth Arnon, who heads the company’s Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone®, a blockbuster drug for the treatment of multiple sclerosis.

BiondVax’s technology utilizes a unique, proprietary combination of conserved and common epitopes from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, for developing, manufacturing and commercializing this innovative flu vaccine.

M-001 has successfully completed 7 human clinical trials. A pivotal, clinical efficacy Phase 3 trial in over 12,000 participants across seven European countries is ongoing.

BiondVax’s team of 20 includes scientists, technicians, researchers, and administrative staff. The company’s state-of-the-art GMP facility in Israel houses its laboratories, production facilities and offices.

Read BiondVax’s Code of Conduct and Business Ethics